The US markets ended considerably higher on Friday after Gilead Sciences (GILD) said remdesivir showed a sharp mortality risk drop when used to treat patients suffering of coronavirus. BioNTech's CEO also said the German biotechnology company's coronavirus vaccine candidate could be ready for approval by December. The upbeat treatment and vaccine news overshadowed the reports that the US saw a record number of new infections of COVID-19, rising by more than 63,000 to mark another single-day record, as hospitals in Texas, California and other states also saw rising hospitalizations from the illness. Total US cases of coronavirus climbed to more than 3.1 million and the death toll topped 133,000, according to data compiled by Johns Hopkins University.
Separately, China said that it would impose reciprocal sanctions against US officials after the US imposed sanctions on individuals and institutions for human rights abuses of Uighurs, a mostly Muslim ethnic minority living in China’s Xinjiang province. In economic data, the wholesale cost of US goods and services fell by 0.2% in June, reflecting depressed demand in retail and other major parts of the economy caused by the coronavirus pandemic. Looking forward, investors are bracing for corporate earnings reports, which will kick off in earnest next week, with the banking sector slated to deliver quarterly results that are likely to be disappointing.
Dow Jones Industrial Average jumped 369.21 points or 1.44 percent to 26,075.3, Nasdaq gained 69.69 points or 0.66 percent 10,617.44 and S&P 500 was up by 32.99 points or 1.05 percent to 3,185.04.
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: